

14



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/762,006	02/01/2001	Thomas Hottkowitz	2923-123	6539

6449 7590 06/15/2004

ROTHWELL, FIGG, ERNST & MANBECK, P.C.
 1425 K STREET, N.W.
 SUITE 800
 WASHINGTON, DC 20005

EXAMINER

STOCKTON, LAURA

ART UNIT	PAPER NUMBER
----------	--------------

1626

DATE MAILED: 06/15/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/762,006

Applicant(s)

HOTTKOWITZ, THOMAS

Examiner

Laura L. Stockton, Ph.D.

Art Unit

1626

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 28 May 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-13, 15, 33 and 43-45 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-13, 15, 33 and 43-45 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____.
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____.

DETAILED ACTION

Claims 1-13, 15, 33 and 43-45 are pending in the application.

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114 was filed in this application after appeal to the Board of Patent Appeals and Interferences, but prior to a decision on the appeal. Since this application is eligible for continued examination under 37 CFR 1.114 and the fee set forth in 37 CFR 1.17(e) has been timely paid, the appeal has been withdrawn pursuant to 37 CFR 1.114 and prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on May 28, 2004 has been entered.

Election/Restrictions

Applicants' election with traverse of Group XI and the species of compound 372 in Paper No. 9 (filed June 14, 2002) was acknowledged

in the Office Action mailed July 11, 2002 {Paper No. 10}. The requirement was deemed proper and made FINAL.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-13, 15, 33 and 43-45 are rejected under 35 U.S.C. 103(a) as being unpatentable over AT 393505 and Eibl et al. {EP 534,445}, each taken alone. English translations of AT 393505 and Eibl et al. are being provided with this Office Action and will be referred to hereinafter unless otherwise specified.

Determination of the scope and content of the prior art (MPEP §2141.01)

Applicants claim phosphates and phosphoamines. AT 393505 teaches phosphates and phosphoamines which are structurally similar to

the instant claimed compounds {see pages 3, 4, 17 and 22-25; and especially Example 13 (page 41) and Example 14 (pages 42-43)}. Eibl et al. also teach phosphate esters which are structurally similar to the instant claimed compounds {page 2, lines 25-42 and Example 5 (Beispiel 5) on page 6 in the EP document; and pages 3-8 in the English translation}.

Ascertainment of the difference between the prior art and the claims (MPEP §2141.02)

The difference between the compounds of the prior art and the compounds instantly claimed is that the instant claimed compounds are generically described in the prior art.

Finding of prima facie obviousness--rational and motivation (MPEP §2142-2413)

The indiscriminate selection of “some” among “many” is *prima facie* obvious. The motivation to make the claimed compounds derives from the expectation that structurally similar compounds would possess similar activity (e.g., cytotoxic activity).

One skilled in the art would thus be motivated to prepare compounds embraced by the prior art to arrive at the instant claimed compounds with the expectation of obtaining additional beneficial products which would have cytotoxic activity and can be used to treat tumors. The instant claimed invention would have been suggested to one skilled in the art and therefore, the instant claimed invention would have been obvious to one skilled in the art.

Response to Arguments

Applicants' arguments filed May 28, 2004 have been fully considered. Applicants argue that the claims, as amended, are unobvious over the compounds in AT 393505 and Eibl et al. Applicants argue that the double bond not being in the same position as it would be in the naturally occurring alcohol or acid allow one to change and specifically control the physical, biochemical and biological properties of the compounds. Applicants allege that such structural variations in the apolar region lead to compounds exhibiting improved antitumor activity.

Applicants further argue that nothing in the art would motivate one skilled in the art to undertake such modifications.

All of Applicants' arguments have been considered but have not been found persuasive. The above cited prior art generically teach the instant invention as presently claimed. The specific examples prepared in the prior art references differ from Applicants' compounds by a methylene group {e.g., $-\text{CH}_2-$ }.

For instance, in comparison of instant claim 1 and Example 14 on pages 42-43 in AT 393505, the difference is a methylene group. See in instant claim 1 wherein $p+q$ is 13 (p is 8 and q is 5) and Example 14 in AT 393505 wherein $p+q$ is 12 (p is 8 and q is 4). The difference being a pentyl group (the value of the instant q variable is 5) in the instant claimed invention versus a butyl group in the prior art (the value of the instant q variable is 4). AT 393505 teach that the "R" variable represents an alkyl residue, having one double bond, with 14 to 20 carbon atoms (page 4, second and third full paragraphs). Therefore, AT 393505 not only prepares a compound that is a homologue of the instant

claimed compounds but generically teaches the compounds embraced by the instant claims. Therefore, the examples in the prior art would lead one skilled in the art to the instant claimed invention. Further, Applicants have not demonstrated in a side-by-side showing of unexpected beneficial results of the instant claimed compounds over the specie prepared in the cited prior art. The rejection of the claims is deemed proper and is therefore maintained.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Laura L. Stockton whose telephone number is (571) 272-0710. The examiner can normally be reached on Monday-Friday from 6:15 am to 2:45 pm. If the examiner is out of the Office, the examiner's supervisor, Joseph McKane, can be reached on (571) 272-0699.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Application/Control Number: 09/762,006
Art Unit: 1626

Page 8

The Official fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

A handwritten signature in black ink, appearing to read "Laura L. Stockton", written over a horizontal line.

Laura L. Stockton, Ph.D.

Patent Examiner

Art Unit 1626, Group 1620

Technology Center 1600

June 10, 2004